Today@Dal

Participants needed: Healthy, premature babies less than 6 months old

Respiratory syncytial virus (RSV) is a virus (germ) that causes breathing problems (respiratory tract infections) in young children and infants. It is present in the community every winter. In the first year of life, about half of all infants become infected with RSV. By 3 years of age, almost all children have been infected with this virus. RSV infection can range from a mild illness like a cold or a sore or swollen throat (pharyngitis) to more severe infections of the lungs such as bronchiolitis and pneumonia (lung infection). The more severe infections may require medical attention, including hospitalizations.

The purpose of the study is to find out how effective REGN2222 is at reducing medical visits for RSV infection in premature babies (32 weeks gestational age to 35 weeks gestational age). REGN2222 is being studied for prevention of lower respiratory tract (lung) infection due to RSV infection.

This study is sponsored by Regeneron Pharmaceuticals; a company that makes and sells vaccines, medicines, and health products.

Participation in the study involves a total of 7 scheduled visits to the IWK Health Centre over a period of about 8-9 months. Study staff will call you at 7 scheduled telephone contacts and weekly between visits. The total time commitment is 6-8 hours. Additional unscheduled visits may occur if your child develops a respiratory illness that requires a doctor visit or if they develop certain side effects and need to be seen.

Participants will be compensated for their time and for out-of-pocket expenses such as travel costs to and from study visits, and a parking pass at the end of each visit if required. The study drug will be provided to you without charge.

As reimbursement for their time commitment to the study and transportation costs to and from the study center, participants will receive $50 for each visit with a study drug injection and $50 for any blood sample visits. Participants will be paid $350.00 in total, and will also receive $50/visit for any unscheduled visits.

Contact Jill to learn more about this study:
902-470-3860
jill.mutch@iwk.nshealth.ca